Clinical Infectious Diseases

Journal

Publication Venue For

  • Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States.  73:e1927-e1935. 2021
  • Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study..  73:e1282-e1289. 2021
  • Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men..  73:1119-1124. 2021
  • Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial.  73:e672-e679. 2021
  • Rapid Antiretroviral Therapy: Time for a new Standard of Care.  73:134-136. 2021
  • COVID-19-Lessons Learned and Questions Remaining.  72:2225-2240. 2021
  • It Is Time to Focus on Asymptomatic Tuberculosis.  72:E1044-E1046. 2021
  • Major Adverse Cardiovascular Events during Invasive Pneumococcal Disease Are Serotype Dependent.  72:E711-E719. 2021
  • Timing of Antiretroviral Therapy Initiation and Risk of Cancer among Persons Living with Human Immunodeficiency Virus.  72:1900-1909. 2021
  • Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.  72:1820-1822. 2021
  • High prevalence of anal high-grade squamous intraepithelial lesions, and prevention through human papillomavirus vaccination, in young men who have sex with men living with HIV. 2021
  • Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus.  72:1529-1537. 2021
  • The Prevalence and Burden of Non-AIDS Comorbidities Among Women Living With or at Risk for Human Immunodeficiency Virus Infection in the United States.  72:1301-1311. 2021
  • Comparing Nasopharyngeal and Midturbinate Nasal Swab Testing for the Identification of Severe Acute Respiratory Syndrome Coronavirus 2.  72:1253-1255. 2021
  • Cryptococcal Antigen in Serum and Cerebrospinal Fluid for Detecting Cryptococcal Meningitis in Adults Living with Human Immunodeficiency Virus: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies.  72:1268-1278. 2021
  • The Evidence Supporting the Revised EORTC/MSGERC Definitions for Invasive Fungal Infections.  72:S77-S78. 2021
  • Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. 2021
  • "rapid Start" Treatment to End the (Other) Epidemic: Walking the Tightrope without a Net.  72:479-481. 2021
  • Breast Milk and COVID-19: What Do We Know?.  72:131-132. 2021
  • Reply to simon and to eljaaly and nix.  63:287-288. 2021
  • The HIV Index: Using a Patient-Reported Outcome on Engagement in HIV Care to Explain Sub-Optimal Retention in Care and Virologic Control. 2020
  • Reply to Luppi et al.  71:3266. 2020
  • Clinic-level factors associated with retention in care among people living with human immunodeficiency virus in a multisite US Cohort, 2010–2016.  71:2592-2598. 2020
  • Longitudinal care cascade outcomes among people eligible for antiretroviral therapy who are newly linking to care in Zambia: A multistate analysis.  71:E561-E570. 2020
  • Prevalence of mycoplasma genitalium infection, antimicrobial resistance mutations, and symptom resolution following treatment of urethritis.  71:E624-E632. 2020
  • Reply to Herbrecht et al.  71:2774-2775. 2020
  • Intersecting Epidemics: Incident Syphilis and Drug Use in Women Living with Human Immunodeficiency Virus in the United States (2005-2016).  71:2405-2413. 2020
  • Reply to Mafaciolli and Pasqualotto.  71:2542-2543. 2020
  • Candidatus Mycoplasma haemohominis: Emerging Infection in New Caledonia. 2020
  • Food insecurity is associated with lower levels of antiretroviral drug concentrations in hair among a cohort of women living with human immunodeficiency virus in the United States.  71:1517-1523. 2020
  • Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium.  71:1367-1376. 2020
  • Decreasing High Risk Exposures for Healthcare-workers through Universal Masking and Universal SARS-CoV-2 Testing upon entry to a Tertiary Care Facility. 2020
  • We thought we created a safety net. We were wrong. 2020
  • Viral kinetics and resistance development in children treated with neuraminidase inhibitors: The influenza resistance information study (IRIS).  71:1186-1194. 2020
  • Resistance of influenza virus to antiviral medications.  71:1092-1094. 2020
  • Meningoencephalitis due to spotted fever rickettsioses, including rocky mountain spotted fever.  71:188-195. 2020
  • Outpatient urinary tract infections in an era of virtual healthcare: Trends from 2008 to 2017.  71:100-108. 2020
  • What's All This Fuss I Hear About Viral "Blips"?.  70:2710-2711. 2020
  • Making the most of point-of-care testing for sexually transmitted diseases.  70:1824-1825. 2020
  • Contribution of congenital cytomegalovirus infection to permanent hearing loss in a highly seropositive population: The brazilian cytomegalovirus hearing and maternal secondary infection study.  70:1379-1384. 2020
  • Development of new antimicrobials for urogenital gonorrhea therapy: Clinical trial design considerations.  70:1495-1500. 2020
  • Reply to Tascini et al.  70:1523-1524. 2020
  • Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia with Anal Cancer Risk in Persons Living with HIV in the United States and Canada.  70:1176-1185. 2020
  • Histoplasmosis: Time to Redraw the Map and Up Our Game.  70:1011-1013. 2020
  • Blood transcriptomic stratification of short-term risk in contacts of tuberculosis.  70:731-737. 2020
  • Impact of abstinence and of reducing illicit drug use without abstinence on human immunodeficiency virus viral load.  70:867-874. 2020
  • Changes in Bone Mass after Discontinuation of Preexposure Prophylaxis with Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex with Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.  70:687-691. 2020
  • Letter to the Editor.  70:718-719. 2020
  • A multicenter, longitudinal cohort study of cryptococcosis in human immunodeficiency virus-negative people in the United States.  70:252-261. 2020
  • Maternal Cytomegalovirus Infection and Fetal Impairment: Uncertainty Remains.  70:174. 2020
  • Trichomonas vaginalis Virus among Women with Trichomoniasis and Associations with Demographics, Clinical Outcomes, and Metronidazole Resistance.  69:2170-2176. 2019
  • Prevalence of Congenital Cytomegalovirus Infection and Associated Risk of in Utero Human Immunodeficiency Virus (HIV) Acquisition in a High-HIV Prevalence Setting, South Africa.  69:1789-1796. 2019
  • Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) after Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.  69:1345-1352. 2019
  • Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction.  69:1136-1143. 2019
  • Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial among Preschool-Aged Children in Urban Bangladesh.  69:777-785. 2019
  • The Effect of Preexisting Immunity on Virus Detection and Immune Responses in a Phase II, Randomized Trial of a Russian-Backbone, Live, Attenuated Influenza Vaccine in Bangladeshi Children.  69:786-794. 2019
  • Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.  68:1981-1989. 2019
  • Plasma 25-Hydroxyvitamin D and the Longitudinal Risk of Sepsis in the REGARDS Cohort.  68:1926-1931. 2019
  • Impact of infectious disease consultation on clinical management and mortality in patients with candidemia.  68:1585-1587. 2019
  • Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.  68:1136-1143. 2019
  • Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.  68:1144-1151. 2019
  • A 9-Point Risk Assessment for Patients Who Inject Drugs and Require Intravenous Antibiotics: Focusing Inpatient Resources on Patients at Greatest Risk of Ongoing Drug Use.  68:1041-1043. 2019
  • Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: A randomized, single-blind, phase 2, controlled trial.  68:803-809. 2019
  • Depressive Symptoms and Engagement in Human Immunodeficiency Virus Care Following Antiretroviral Therapy Initiation.  68:475-481. 2019
  • Molecular-based testing for sexually transmitted infections using samples previously collected for vaginitis diagnosis.  68:375-381. 2019
  • Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition.  68:87-95. 2019
  • The North-South divide: Substance use risk, care engagement, and viral suppression among hospitalized human immunodeficiency virus-infected patients in 11 US cities.  68:146-149. 2019
  • Cumulative burden of depression and all-cause mortality in women living with human immunodeficiency virus.  67:1575-1581. 2018
  • A Brief History of Evolving Diagnostics and Therapy for Gonorrhea: Lessons Learned.  67:1294-1299. 2018
  • Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia.  67:1269-1277. 2018
  • No Impact of Hepatitis B Virus Infection on Early Mortality among Human Immunodeficiency Virus-Infected Patients in Southern Africa.  67:1310-1311. 2018
  • Large Outbreak of Hepatitis C Virus Associated with Drug Diversion by a Healthcare Technician.  67:845-853. 2018
  • Cytomegalovirus Shedding in Seropositive Pregnant Women from a High-Seroprevalence Population: The Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study.  67:743-750. 2018
  • Why does trichomonas vaginalis continue to be a "neglected" sexually transmitted infection?.  67:218-220. 2018
  • A silent epidemic: The prevalence, incidence and persistence of mycoplasma genitalium among young, asymptomatic high-risk women in the United States.  67:73-79. 2018
  • Association of Neighborhood Socioeconomic Status with Risk of Infection and Sepsis.  66:1940-1947. 2018
  • ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants with HIV-1 RNA <500000 Copies/mL.  66:1689-1697. 2018
  • Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel.  66:1678-1686. 2018
  • Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.  66:1794-1797. 2018
  • Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials.  66:1492-1500. 2018
  • Multimorbidity among Persons Living with Human Immunodeficiency Virus in the United States.  66:1230-1238. 2018
  • Management of an Outbreak of Exophiala dermatitidis Bloodstream Infections at an Outpatient Oncology Clinic.  66:959-962. 2018
  • High prevalence of multidrug-resistant mycoplasma genitalium in human immunodeficiency virus-infected men who have sex with men in Alabama.  66:796-798. 2018
  • Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis among Adolescent and Young Men Who Have Sex with Men in the United States.  66:213-219. 2018
  • Improved Retention with 6-Month Clinic Return Intervals for Stable Human Immunodeficiency Virus-Infected Patients in Zambia.  66:237-243. 2018
  • Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with Human Immunodeficiency Virus Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.  66:220-228. 2018
  • Outbreak of Foodborne Botulism in an Immigrant Community: Overcoming Delayed Disease Recognition, Ambiguous Epidemiologic Links, and Cultural Barriers to Identify the Cause.  66:S82-S84. 2017
  • The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus Infection.  65:2042-2049. 2017
  • Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women.  65:1695-1702. 2017
  • Mycoplasma hominis Infections Transmitted Through Amniotic Tissue Product.  65:1152-1158. 2017
  • CD4:CD8 Ratio and CD8 Count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: The antiretroviral therapy cohort collaboration (ART-CC).  65:959-966. 2017
  • Continued evolution of gonococcal antimicrobial resistance.  65:924-926. 2017
  • Cancer-Attributable Mortality among People with Treated Human Immunodeficiency Virus Infection in North America.  65:636-643. 2017
  • Risk of Acute Coronary Heart Disease after Sepsis Hospitalization in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort.  65:29-36. 2017
  • Antiretroviral therapy initiation and changes in self-reported depression.  64:1791-1794. 2017
  • Continuum of care for hepatitis C virus among patients diagnosed in the emergency department setting.  64:1540-1546. 2017
  • Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including raltegravir or efavirenz among adults in the United States.  64:1591-1596. 2017
  • Impact of Antiretroviral Therapy on Liver Fibrosis among Human Immunodeficiency Virus-Infected Adults with and Without HBV Coinfection in Zambia.  64:1343-1349. 2017
  • Diffuse white matter signal abnormalities on magnetic resonance imaging are associated with human immunodeficiency virus type 1 viral escape in the central nervous system among patients with neurological symptoms.  64:1059-1065. 2017
  • Association of Diabetes and Insulin Therapy With Risk of Hospitalization for Infection and 28-Day Mortality Risk..  64:435-442. 2017
  • Association of diabetes and insulin therapy with risk of hospitalization for infection and 28-day mortality risk.  64:435-442. 2017
  • Decline in bone mass with tenofovir disoproxil fumarate/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis.  64:317-325. 2017
  • Angiostrongylus cantonensis infection: A cause of fever of unknown origin in pediatric patients.  63:1475-1478. 2016
  • Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe, and Asia.  63:1245-1253. 2016
  • Durable Viral Suppression and Transmission Risk Potential among Persons with Diagnosed HIV Infection: United States, 2012-2013.  63:976-983. 2016
  • The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study.  63:694-702. 2016
  • Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir.  63:528-531. 2016
  • Editorial Commentary: Affordable Care Act, Medicaid Expansion ... or Not: Ryan White Care Act Remains Essential for Access and Equity.  63:404-406. 2016
  • Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis.  63:186-194. 2016
  • Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy among HIV-infected Patients Followed for up to 15 Years after Start of Treatment: Collaborative Cohort Study.  62:1571-1577. 2016
  • Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor.  62:1329-1335. 2016
  • Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.  62:613-616. 2016
  • Home Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases.  62:531-536. 2016
  • Randomized controlled trial to compare immunogenicity of standard-dose intramuscular versus intradermal trivalent inactivated influenza vaccine in HIV-infected men who have sex with men in Bangkok, Thailand.  62:383-391. 2016
  • A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.  61:S837-S848. 2015
  • Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.  61:S774-S784. 2015
  • Immunization costs and programmatic barriers at an urban HIV clinic.  61:1726-1731. 2015
  • Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.  61:1573-1581. 2015
  • Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.  62:e1-e50. 2015
  • Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.  62:409-417. 2015
  • Host-directed therapies for tackling multi-drug resistant tuberculosis: Learning from the pasteur-bechamp debates.  61:1432-1438. 2015
  • Live animal markets in Minnesota: A potential source for emergence of novel influenza a viruses and interspecies transmission.  61:1355-1362. 2015
  • Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison with Antigen Testing.  61:1293-1303. 2015
  • Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: Effects on endothelial function, lipoproteins, and inflammation.  61:840-849. 2015
  • Herpes simplex encephalitis: Lack of clinical benefit of long-term valacyclovir therapy.  61:683-691. 2015
  • Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections.  61:601-606. 2015
  • Reply to Bauer and Goff.  61:487-488. 2015
  • Dynamic visual display of treatment response in HIV-infected adults.  61:e1-e4. 2015
  • Predicting risk of endocarditis using a clinical tool (PREDICT): Scoring system to guide use of echocardiography in the management of Staphylococcus aureus bacteremia.  61:18-28. 2015
  • End-stage renal disease among HIV-infected adults in North America.  60:941-949. 2015
  • T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial.  60:892-899. 2015
  • Waning efficacy of the herpes zoster vaccine.  60:910-911. 2015
  • Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.  60:713-720. 2015
  • Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.  60:703-712. 2015
  • A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea.  61:1043-1048. 2015
  • Age at Entry into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality among HIV-Seropositive Adults in the United States.  61:1189-1195. 2015
  • Editorial Commentary: Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROL.  61:169-170. 2015
  • Editorial commentary: Women who have sex with women: A unique population for studying the pathogenesis of bacterial vaginosis.  60:1054-1056. 2015
  • Eosinophil-associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to loa-endemic areas.  60:55-63. 2015
  • Fixing a hole in the HIV safety net.  60:126-127. 2015
  • Less Bone Loss with Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.  61:1179-1188. 2015
  • Ten-year survival by race/ethnicity and sex among treated, HIV-infected adults in the United States.  60:1700-1707. 2015
  • Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics.  60:1377-1383. 2015
  • Chronic hepatitis B virus coinfection is associated with renal impairment among zambian HIV-infected adults.  59:1757-1760. 2014
  • The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.  59:1083-1091. 2014
  • Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic.  59:834-841. 2014
  • National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States.  59:755-764. 2014
  • Enhanced personal contact with HIV patients improves retention in primary care: A randomized trial in 6 US HIV clinics.  59:725-734. 2014
  • Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.  59:287-297. 2014
  • Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort.  59:279-286. 2014
  • Reply to rapose.  59:316-317. 2014
  • Reversible blindness in cryptococcal meningitis with normal intracranial pressure: Case report and review of the literature.  59:310-313. 2014
  • Addressing the achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation.  59. 2014
  • HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.  58:1599-1606. 2014
  • Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.  58:1467-1472. 2014
  • Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.  58:1473-1480. 2014
  • Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.  58:1312-1321. 2014
  • MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.  58:1219-1226. 2014
  • Antibiotic hypersensitivity reactions and approaches to desensitization.  58:1140-1148. 2014
  • Disparities in the quality of HIV care when using US department of health and human services indicators.  58:1185-1189. 2014
  • Erratum: Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS) (Clinical Infectious Diseases (2013) 56 (1197-205)).  58:1203. 2014
  • Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.  58:413-422. 2014
  • Church attendance in men who have sex with men diagnosed with HIV is associated with later presentation for HIV care.  58:295-299. 2014
  • An expanded role for therapeutic lumbar punctures in newly diagnosed aids-associated cryptococcal meningitis?.  59:1615-1617. 2014
  • Beyond core indicators of retention in HIV care: Missed clinic visits are independently associated with all-cause mortality.  59:1471-1479. 2014
  • Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care.  59:1686-1693. 2014
  • Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.  58:1297-1307. 2014
  • Case definitions, diagnostic algorithms, and priorities in encephalitis: Consensus statement of the international encephalitis consortium.  57:1114-1128. 2013
  • Reply to Yang et al.  57:1212-1213. 2013
  • The state of engagement in HIV care in the United States: From cascade to continuum to control.  57:1164-1171. 2013
  • A systematic review and meta-regression of temporal trends in adult CD4+ cell count at presentation to HIV care, 1992-2011.  57:1027-1037. 2013
  • Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.  57:735-744. 2013
  • Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy.  57:756-764. 2013
  • Clinical reasoning for the infectious disease specialist: A primer to recognize cognitive biases.  57:573-578. 2013
  • Human infections with influenza A(H3N2) variant virus in the United States, 2011-2012.  57. 2013
  • Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States.  56:1800-1809. 2013
  • Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda.  56:1829-1837. 2013
  • Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.  56:1471-1479. 2013
  • Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The influenza resistance information study (IRIS).  56:1197-1205. 2013
  • Trends and disparities in antiretroviral therapy initiation and Virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.  56:1174-1182. 2013
  • Erratum: Changing epidemiology of herpes simplex virus infections (Clinical Infectious Diseases (2013) 56 (352-353)).  56:1066. 2013
  • Editorial Commentary: Sexual networks, sex hormones, and recurrent bacterial vaginosis: Not such strange bedfellows.  56:787-879. 2013
  • Cardiac disease in adolescents with delayed diagnosis of vertically acquired HIV infection.  56:576-582. 2013
  • Editorial commentary: Changing Epidemiology of Herpes Simplex Virus Infections.  56:352-353. 2013
  • Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.  56:344-351. 2013
  • Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin.  56:420-422. 2013
  • Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke.  56:209-217. 2013
  • Near-universal prevalence of pneumocystis and associated increase in mucus in the lungs of infants with sudden unexpected death.  56:171-179. 2013
  • Congenital cytomegalovirus infection: audiologic outcome..  57 Suppl 4. 2013
  • Congenital cytomegalovirus infection: clinical outcome..  57 Suppl 4. 2013
  • Environmental risk factors for pneumocystis pneumonia hospitalizations in HIV patients.  56:74-81. 2013
  • Editorial commentary: A syphilis wish list: Better data, better tests.  55:1623-1624. 2012
  • Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.  55:1550-1557. 2012
  • Editorial commentary: Viva no différence!.  55:1252-1254. 2012
  • Novel pneumococcal serotypes 6C and 6D: Anomaly or harbinger.  55:1379-1386. 2012
  • A low-effort, clinic-wide intervention improves attendance for HIV primary care.  55:1124-1134. 2012
  • Clinical scoring for risk of resistant organisms in pneumonia: Right idea, wrong interpretation.  55:749-750. 2012
  • Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.  55. 2012
  • Reply to Anaissie and Nucci and to Cisneros et al.  55:894-895. 2012
  • Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent trials network study 021B.  55:461-468. 2012
  • Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection.  55:145-152. 2012
  • Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital chlamydia trachomatis infection: A randomized, double-blind, double-dummy, active-controlled, multicenter trial.  55:82-88. 2012
  • Acquired epidermodysplasia verruciformis due to multiple and unusual HPV infection among vertically-infected, HIV-positive adolescents in Zimbabwe.  54. 2012
  • Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials.  54:1110-1122. 2012
  • Reply to Keynan.  54:1037-1038. 2012
  • Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial.  54:1013-1025. 2012
  • Differential occurrence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of pathogen microevolution.  54:794-799. 2012
  • Patient reported outcomes in routine care: Advancing data capture for HIV cohort research.  54:141-147. 2012
  • Diagnosis and management of uncomplicated chlamydia trachomatis infections in adolescents and adults: Summary of evidence reviewed for the 2010 centers for disease control and prevention sexually transmitted diseases treatment guidelines.  53. 2011
  • Interventions to prevent sexually transmitted infections, including HIV infection.  53. 2011
  • Sexually transmitted infections among women who have sex with women.  53. 2011
  • Trichomonas vaginalis genital infections: Progress and challenges.  53. 2011
  • Essential components of effective HIV care: A policy paper of the HIV medicine association of the infectious diseases society of america and the ryan white medical providers coalition.  53:1043-1050. 2011
  • HIV now firmly established in the middle ages.  53:1140-1142. 2011
  • Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis.  53:1092-1099. 2011
  • The spectrum of engagement in HIV care: Do more than 19%of HIV-infected persons in the US have undetectable viral load?.  53:1168-1169. 2011
  • Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.  53:927-935. 2011
  • Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.  53:807-816. 2011
  • Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort.  53:826-835. 2011
  • Serologically confirmed household transmission of 2009 pandemic influenza a (H1N1) virus during the first pandemic wave - New York City, april-may 2009.  53:455-462. 2011
  • Ocular manifestations of candidemia.  53:262-268. 2011
  • Erratum: High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy (Clinical Infectious Diseases (2011) 52 (378-386)).  52:1200. 2011
  • Comparative effectiveness and toxicity of statins among HIV-infected patients.  52:387-395. 2011
  • High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy.  52:378-386. 2011
  • Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population.  52:396-405. 2011
  • NK cells, innate immunity and hepatitis C infection after liver transplantation.  52:369-377. 2011
  • Health care system and policy factors influencing engagement in HIV medical care: Piecing together the fragments of a fractured health care delivery system.  52. 2011
  • Re-evaluating the treatment of nongonococcal urethritis: Emphasizing emerging pathogens - A randomized clinical trial.  52:163-170. 2011
  • Slowly progressive annular skin lesions in an elderly patient..  52. 2011
  • Reply to Johnson and Stricker.  51:1109-1110. 2010
  • Bone disease in HIV infection: A practical review and recommendations for HIV care providers.  51:937-946. 2010
  • Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.  51:718-724. 2010
  • How do HIV elite controllers do what they do?.  51:239-241. 2010
  • Reply to Hoenigl et al.  51:254-255. 2010
  • Factors associated with mortality in transplant patients with invasive aspergillosis.  50:1559-1567. 2010
  • Late presentation for human immunodeficiency virus care in the United States and Canada.  50:1512-1520. 2010
  • Causes of death in HIV-1-Infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies.  50:1387-1396. 2010
  • Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (Transnet).  50:1101-1111. 2010
  • Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant- associated infection surveillance network (TRANSNET) database.  50:1091-1100. 2010
  • Routine, self-administered, touch-screen, computer-based suicidal ideation assessment linked to automated response team notification in an HIV primary care setting.  50:1165-1173. 2010
  • Erratum: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. (Clinical Infectious Diseases (2009) 49:(1-45)).  50:1079. 2010
  • Blastomycosis of the central nervous system: A multicenter review of diagnosis and treatment in the modern era.  50:797-804. 2010
  • Sex and gender differences in travel-associated disease.  50:826-832. 2010
  • Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.  50:912-919. 2010
  • Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care.  50:574-584. 2010
  • Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America.  50:291-322. 2010
  • Cryptococcosis in the developing world: An elephant in the parlor.  50:345-346. 2010
  • Erratum: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. (Clin Infect Dis (2009) 49 (1-45)).  50:457. 2010
  • Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.  50:221-228. 2010
  • Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent trials network study 021.  50:106-114. 2010
  • Reply to Collins et al and Manian.  49:1771-1772. 2009
  • Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.  49:1582-1590. 2009
  • Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter study.  49:931-934. 2009
  • Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population.  49:522-528. 2009
  • Reply to kontoyiannis.  49:639-640. 2009
  • Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America.  49:1-45. 2009
  • A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.  48:1775-1783. 2009
  • HIV policy: The path forward- A joint position paper of the HIV medicine association of the infectious diseases society of America and the American College of physicians.  48:1335-1344. 2009
  • Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal.  48:1138-1151. 2009
  • Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.  48:787-794. 2009
  • Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America.  48:503-535. 2009
  • Missed visits and mortality among patients establishing initial outpatient HIV treatment.  48:248-256. 2009
  • Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria.  47:674-683. 2008
  • Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries.  47:487-495. 2008
  • The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America.  47:303-327. 2008
  • Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (Clinical Infectious Diseases (2007) 45, (883-893)).  47:302. 2008
  • Clinical practice guidelines for the management of blastomycosis: 2008 Update by the infectious diseases society of America.  46:1801-1812. 2008
  • Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.  46:1813-1821. 2008
  • Lactational amenorrhea as a risk factor for group a streptococcal vaginitis.  46. 2008
  • Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV Clinic.  46:1315-1318. 2008
  • High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.  46:1111-1118. 2008
  • Seasonal and pandemic influenza: A 2007 update on challenges and solutions.  46:1024-1031. 2008
  • Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.  46:625-633. 2008
  • Reply to Eiland et al..  46:641. 2008
  • Reply to Connor.  46:476-477. 2008
  • Opt-out testing: Who can afford to take care of patients with newly diagnosed HIV infection?.  45. 2007
  • Clinical practice guidelines for the management of sporotrichosis: 2007 Update by the Infectious Diseases Society of America.  45:1255-1265. 2007
  • Expanding the spectrum of pathogens in urethritis: Implications for presumptive therapy?.  45:872-874. 2007
  • Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.  45:883-893. 2007
  • The incidence and severity of herpes simplex encephalitis in Sweden, 1990-2001.  45:881-882. 2007
  • Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.  45:658-661. 2007
  • Persistence of nevirapine in breast milk after discontinuation of treatment.  45:391-394. 2007
  • Failure to establish HIV care: Characterizing the "no show" phenomenon.  45:127-130. 2007
  • Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: Evidence reviewed for the 2006 centers for disease control and prevention sexually transmitted diseases treatment guidelines.  44. 2007
  • Management of women with cervicitis.  44. 2007
  • HIV infection presenting in older children and adolescents: A case series from Harare, Zimbabwe.  44:874-878. 2007
  • Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.  44:726-734. 2007
  • Reply to Behrens et al. [4].  44:762-763. 2007
  • Factors associated with seronegative chronic hepatitis C virus infection in HIV infection.  44:577-583. 2007
  • A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis.  44:213-219. 2007
  • Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients.  44:245-249. 2007
  • Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?.  44:135-138. 2007
  • Recommendations for the management of herpes zoster.  44. 2007
  • Trichomonas vaginalis infection in male sexual partners: Implications for diagnosis, treatment, and prevention.  44:13-22. 2007
  • Trichomonas vaginalis infection: The most prevalent nonviral sexually transmitted infection receives the least public health attention.  44:23-25. 2007
  • The practice of travel medicine: Guidelines by the infectious diseases society of America.  43:1499-1539. 2006
  • Which policy to ADAP-T: Waiting lists or waiting lines?.  43:1365-1367. 2006
  • Recurrent benign lymphocytic meningitis.  43:1194-1197. 2006
  • Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.  43:1135-1142. 2006
  • Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt.  43:1031-1039. 2006
  • Reply to Tong et al. [4].  43:542-544. 2006
  • Invasive fungal pathogens: Current epidemiological trends.  43. 2006
  • Antifungal therapy: Lessons learned over the past 27 years.  42:1289-1296. 2006
  • Distribution of health care expenditures for HIV-infected patients.  42:1003-1010. 2006
  • Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.  42:870-877. 2006
  • Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study.  42:401-407. 2006
  • Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.  42:126-131. 2006
  • Family outbreaks of invasive community-associated methicillin-resistant Staphylococcus aureus infection..  42. 2006
  • Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.  41:1326-1332. 2005
  • Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons.  41:1045-1048. 2005
  • Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans.  41:654-659. 2005
  • Trends in cancer incidence rates among HIV-infected patients [3] (multiple letters).  41:124-127. 2005
  • Risk of congenital cytomegalovirus infection [2] (multiple letters).  40:1701-1703. 2005
  • The use of dexamethasone in bacterial meningitis [2] (multiple letters).  40:1061-1063. 2005
  • Human herpesvirus 6 infection of the central nervous system: Is it just a case of mistaken association?.  40:894-895. 2005
  • Managing cryptococcal meningitis is about handling the pressure.  40:480-482. 2005
  • Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center..  40. 2005
  • Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America.  39:1307-1313. 2004
  • Practice guidelines for the management of bacterial meningitis.  39:1267-1284. 2004
  • Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.  39:1380-1384. 2004
  • Clinical and therapeutic management of pulmonary Mycobacterium xenopi infection in HIV-positive patients [3] (multiple letters).  38:1642-1644. 2004
  • Anemia in HIV infection: Clinical impact and evidence-based management strategies.  38:1454-1463. 2004
  • Antiretroviral drug content in products from developing countries.  38:1317-1319. 2004
  • Interval between births and risk of congenital cytomegalovirus infection.  38:1035-1037. 2004
  • Guidelines for Treatment of Candidiasis.  38:161-189. 2004
  • Donor-Related Coccidioidomycosis in Organ Transplant Recipients.  37:1265-1269. 2003
  • Human Immunodeficiency Virus Type 1-Related Pulmonary Mycobacterium xenopi Infection: A Need to Treat?.  37:1250-1254. 2003
  • A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.  37:634-643. 2003
  • Duration of highly active antiretroviral therapy regimens.  37:714-722. 2003
  • Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution.  36:1539-1544. 2003
  • A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.  36:1221-1228. 2003
  • Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus.  36:373-377. 2003
  • A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: Correlations with CD4 cell count and plasma HIV-1 RNA level.  36:207-211. 2003
  • Comparative analysis of commercial assays for the detection and quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C.  35:323-325. 2002
  • Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A report of 12 cases.  33:1914-1921. 2001
  • The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis.  33:1824-1833. 2001
  • Distribution of Pneumocystis carinii f. sp. hominis types in the lung of a child dying of Pneumocystis pneumonia.  33:100-102. 2001
  • Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.  33:690-699. 2001
  • Invasive mold infections in allogeneic bone marrow transplant recipients.  32:1319-1324. 2001
  • Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons.  32:1215-1220. 2001
  • Internet and computer-based resources for travel medicine practitioners.  32:757-765. 2001
  • Influence of the normal menstrual cycle on vaginal microflora [6].  32:325. 2001
  • Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32: 320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32: 321) [1].  32:518-519. 2001
  • Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.  30. 2000
  • A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficieney virus-infected individuals.  30:540-544. 2000
  • Introduction to antifungal drugs..  30:653-657. 2000
  • Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo.  30:19-24. 2000
  • Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis.  30:47-54. 2000
  • Sporotrichosis in Peru: Description of an area of hyperendemicity.  30:65-70. 2000
  • Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998.  31:76-79. 2000
  • Practice guidelines for the management of cryptococcal disease.  30:710-718. 2000
  • Practice guidelines for the management of patients with blastomycosis.  30:679-683. 2000
  • Practice guidelines for the treatment of candidiasis.  30:662-678. 2000
  • Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.  31:1095-1097. 2000
  • Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.  30:749-756. 2000
  • Screening for latent tuberculosis in sexually transmitted disease clinics [4].  30:986. 2000
  • Serological survey and active surveillance for La Crosse virus infections among children in Tennessee.  31:1284-1287. 2000
  • A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group..  28:291-296. 1999
  • A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis.  28:291-298. 1999
  • Carriage of multidrug-resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care center.  29:1257-1264. 1999
  • Newly recognized focus of La Crosse encephalitis in Tennessee.  28:93-97. 1999
  • Herpes simplex viruses.  26:541-555. 1998
  • Vertebral blastomycosis with paravertebral abscess: Report of eight cases and review of the literature.  26:413-418. 1998
  • An outbreak of multidrug resistant pneumococcal meningitis in a day care center.  25:361. 1997
  • Capsular polysaccharide types of group b streptococcal isolates from neonates wtth early-onset systemic infection.  25:439. 1997
  • Changing frequency of early-onset group B streptococcal disease(EOGBS) in neonates from 1992 to 1996.  25:409. 1997
  • Cryptococcosis in non-HIV infected patients: A multicemer survey.  25:379. 1997
  • Current trends in nosocomial candidemia: Results of a large multienter study.  25:357. 1997
  • Effects of primary maternal cmv infection on early pregnancy and the immature placenta in guinea pigs.  25:375. 1997
  • Long term virological and immunological effect of the HIV protease inhibitor, VIRACEPT® (nelfinavir mesylate, NFV) in combination with zidovudine (AZT) and lamivudine (3TC).  25:396. 1997
  • Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  25:200-205. 1997
  • Cardiac arrhythmias associated with coadministration of azole compounds and cisapride [4] (multiple letters).  24:1285. 1997
  • Treatment of blastomycosis with higher doses of fluconazole.  25:200-205. 1997
  • Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  23:996-1001. 1996
  • Fluconazole therapy for histoplasmosis.  23:996-1001. 1996
  • Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials.  22:341-347. 1996
  • Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.  22:46-50. 1996
  • Update on the management of onychomycosis: Highlights on the Third Annual International Summit on Cutaneous Antifungal Therapy.  23:305-313. 1996
  • Herpes zoster in patients with human immunodeficiency virus infection--an ever-expanding spectrum of disease..  21:989-990. 1995
  • Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group..  21:994-996. 1995
  • Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  20:267-271. 1995
  • Editorial response: Herpes zoster in patients with human immunodeficiency virus infection–an ever-expanding spectrum of disease.  21:989-990. 1995
  • Editorialresponse: Clinical and host differences between infections with the two varieties of cryptococcus neoformans.  21:35-36. 1995
  • Guidelines for the prevention and treatment of B-virus infections in exposed persons.  20:421-439. 1995
  • Herpes simplex virus infections of the central nervous system: Therapeutic and diagnostic considerations.  20:414-420. 1995
  • Herpesvirus infections in persons infected with human immunodeficiency virus.  21. 1995
  • Human herpesvirus 6 is associated with focal encephalitis.  21:571-576. 1995
  • Intravascular catheter exchange and duration of candidemia.  21:994-996. 1995
  • Pentamidine Concentrations in a Mother with AIDS and in Her Neonate.  20:1569-1570. 1995
  • Treatment of blastomycosis with fluconazole: A pilot study.  20:267-271. 1995
  • USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations.  21. 1995
  • Diagnosing neurosyphilis..  18:295-297. 1994
  • Editorial response: Diagnosing neurosyphilis.  18:295-297. 1994
  • Human immunodeficiency virus infection.  18:963-973. 1994
  • Intraocular blastomycosis: Case report and review.  18:805-807. 1994
  • Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of aids-associated cryptococcal meningitis.  18:789-792. 1994
  • Pulmonary infection due to legionella cincinnatiensis in renal transplant recipients: Two cases and implications for laboratory diagnosis.  18:385-389. 1994
  • Evaluation of new anti-infective drugs for the treatment of infection with human immunodeficiency virus.  17:794-801. 1993
  • Evaluation of new anti-infective drugs for the treatment of infection with human immunodeficiency virus. The European Working Party of the European Society of Clinical Microbiology and Infectious Diseases..  17:794-801. 1993
  • Radiographic Changes Associated with Tracheal Isolation of Ureaplasma Urealyticum from Neonates.  17:S122-S130. 1993
  • Systemic Neonatal Infection Due to Ureaplasma urealyticum.  17:S131-S135. 1993
  • Therapeutic Considerations for Ureaplasma urealyticum Infections in Neonates.  17:S208-S214. 1993
  • Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S182-S188. 1992
  • Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S189-S194. 1992
  • Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S200-S205. 1992
  • Evaluation of new anti-infective drugs for the treatment of viral encephalitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S195-S199. 1992
  • Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis.  15:S182-S188. 1992
  • Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis.  15:S189-SI94. 1992
  • Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis.  15:S200-S205. 1992
  • Evaluation of new anti-infective drugs for the treatment of viral encephalitis.  15:S195-S199. 1992
  • Geographic Distribution of Penicillin-Resistant Clones of Streptococcus pneumoniae: Characterization by Penicillin-Binding Protein Profile, Surface Protein A Typing, and Multilocus Enzyme Analysis.  15:112-118. 1992
  • The management of pregnancies complicated by genital infections with herpes simplex virus.  15:1031-1038. 1992
  • International Standard Serial Number (issn)

  • 1058-4838
  • Electronic International Standard Serial Number (eissn)

  • 1537-6591